<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="455">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100942</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-445-4189</org_study_id>
    <secondary_id>2016-003558-34</secondary_id>
    <nct_id>NCT03100942</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren's Syndrome</brief_title>
  <official_title>A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of filgotinib, GS-9876, and
      tirabrutinib (formerly GS-4059) in adults with active Sjogren's Syndrome (SjS).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>Response is defined in the protocol as composite improvement of biologic and patient reported outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
    <description>The ESSDAI is a physician-administered tool designed to measure disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
    <description>The ESSPRI is a patient-reported questionnaire to assess subjective patient symptoms and includes 3 domains (dryness, pain, and fatigue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ESSDAI at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The ESSDAI is a physician-administered tool designed to measure disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ESSPRI at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The ESSPRI is a patient-reported questionnaire to assess subjective patient symptoms and includes 3 domains (dryness, pain, and fatigue).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib + GS-9876 placebo + tirabrutinib placebo for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9876</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9876 + filgotinib placebo + tirabrutinib placebo for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirabrutinib + filgotinib placebo + GS-9876 placebo for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then active treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Filgotinib placebo + GS-9876 placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants on placebo will be rerandomized to receive either filgotinib, GS-9876, or tirabrutinib, in a blinded fashion and will continue treatment through Week 48.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>200 mg tablet administered orally once daily</description>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_label>Placebo, then active treatment</arm_group_label>
    <other_name>GS-6034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9876</intervention_name>
    <description>30 mg tablet administered orally once daily</description>
    <arm_group_label>GS-9876</arm_group_label>
    <arm_group_label>Placebo, then active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirabrutinib</intervention_name>
    <description>40 mg tablet administered orally once daily</description>
    <arm_group_label>Tirabrutinib</arm_group_label>
    <arm_group_label>Placebo, then active treatment</arm_group_label>
    <other_name>GS-4059</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>GS-9876</arm_group_label>
    <arm_group_label>Tirabrutinib</arm_group_label>
    <arm_group_label>Placebo, then active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9876 placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_label>Tirabrutinib</arm_group_label>
    <arm_group_label>Placebo, then active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirabrutinib placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_label>GS-9876</arm_group_label>
    <arm_group_label>Placebo, then active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosed with SjS according to American European Consensus Group (AECG)
             classification

          -  Active SjS as defined by an ESSDAI â‰¥ 5

          -  Seropositivity for antibodies to SjS-associated antigens A and B (anti-SSA or
             anti-SSB)

        Key Exclusion Criteria:

          -  Concurrent treatment with any biologic disease modifying antirheumatic drug (bDMARD)
             (prior bDMARD treatment allowed with appropriate washout as per study protocol)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>GS-US-445-4189@gilead.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>March 31, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
